Rigel Pharmaceuticals (RIGL) Reports Q4 Earnings: It’s A Beat

Rigel Pharmaceuticals, Inc. (RIGL) is flat to $3.11 in pre-market trading after it reported fiscal results for the fourth quarter.

In its quarterly report, the drug developer said it earned ($0.25) per share, above the ($0.27) per share analysts were expecting. Revenue rose 43.5% to $8.25 million, well above views for $2.5 million.

For the full-year 2014, Rigel reported contract revenues of $8.3 million and a net loss of $90.9 million, or $1.04 per share, compared to $7.2 million and a net loss of $89.0 million, or $1.02 per share, in 2013.

On valuation measures, Rigel Pharmaceuticals Inc. shares, which currently have an average 3-month trading volume of 797,088 shares, trade with a t-12 P/S ratio of 45.65. Price/book is 1.79. The high Wall Street price target on the name is $10.00. Currently ticker boasts 1 ‘Buy’ endorsements, compared to 4 ’Holds’ and no ‘Sell’.

Profitability-wise, RIGL has a t-12 operating margin of (1,492%). The $273.03 million market cap company reported $143.16 million in cash – compared to $212 million yoy – versus $0 in debt in its most recent quarter.

RIGL currently prints a one year loss of about 10% and a year-to-date return of around 37%.

The chart below shows where the equity has traded over the last 52 weeks.

Rigel Pharmaceuticals Inc. is a clinical-stage drug development company that develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. The company was founded in 1996 and is based in South San Francisco, California.

Create Content With AI

Try TradingView For Free

Risk Our Money Not Yours | Get 50% Off Any Account

Disclaimer: This page contains affiliate links. If you choose to make a purchase after clicking a link, we may receive a commission at no additional cost to you. Thank you for your support!

Be the first to comment

Leave a Reply

Your email address will not be published.


This site uses Akismet to reduce spam. Learn how your comment data is processed.